SNS-229

SNS-229 is a small molecule investigational drug identified as a potent and selective inhibitor of 3-phosphoinositide-dependent protein kinase 1 (PDK1). It binds the inactive conformation of PDK1 and induces a conformational change that impairs the PIF-pocket, leading to inhibition of PIF-mediated substrate binding and downstream signaling, distinct from ATP-competitive PDK1 inhibitors. Preclinical studies have demonstrated that SNS-229 shows broad anti-proliferative activity and induces apoptosis in various hematologic cancer cell lines—including those resistant to PI3K and AKT inhibitors—and causes significant tumor growth inhibition and regression in animal xenograft models. Pharmacokinetic studies in mice show good oral bioavailability. SNS-229 was developed by Sunesis Pharmaceuticals as part of a novel class of PDK1 inhibitors aimed at oncology indications, particularly hematologic malignancies and solid tumors[1][4][11][13][15][17]. No clinical trials for SNS-229 in non-oncological indications or other mechanisms have been identified.